	US 12,391,758 B2
	Anti-PD-L1 cancer immunotherapy antibodies
Chiang J. Li, Cambridge, MA (US); Shyam Unniraman, Newton, MA (US); Hannah Bader, Waltham, MA (US); and Mithilesh Jha, Sharon, MA (US)
Assigned to 1GLOBE BIOMEDICAL CO., LTD., Beijing (CN); and 1GLOBE HEALTH INSTITUTE LLC, Norwood, MA (US)
Appl. No. 17/270,034
Filed by 1GLOBE BIOMEDICAL CO., LTD., Beijing (CN); and 1GLOBE HEALTH INSTITUTE LLC, Norwood, MA (US)
PCT Filed Aug. 20, 2019, PCT No. PCT/CN2019/101659 § 371(c)(1), (2) Date Feb. 21, 2021, PCT Pub. No. WO2020/038379, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/720,015, filed on Aug. 20, 2018.
Prior Publication US 2021/0332138 A1, Oct. 28, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 45/06 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. An antigen-binding polypeptide that binds to a human PD-L1 epitope, comprising a heavy chain variable domain and a light chain variable domain having respective PD-L1-specific sequences, wherein the respective PD-L1-specific sequences consist of a sequence pairing selected from the group consisting of:

(a) SEQ ID NO: 18 and SEQ ID NO: 20;

(b) SEQ ID NO: 42 and SEQ ID NO: 44;

and